JUNSHI BIO announced that the company received the "Supplementary Drug Application Approval Notice" approved and issued by the National Medical Products Administration, stating that Triplizumab (trade name: Tuoyi, product code: JS1) is approved for the indication of treating unresectable or metastatic melanoma that has failed previous systemic therapy, transitioning from conditional approval to regular approval.
君实生物：特瑞普利单抗二线及以上治疗黑色素瘤获常规批准
JUNSHI BIO: Triplizumab has received regular approval for second-line and above treatment of melanoma.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated